



(C<sub>4</sub>)haloalkoxy, nitro, cyano, (C<sub>1</sub>-C<sub>4</sub>)acyl, amino, (C<sub>1</sub>-C<sub>4</sub>)alkylamino, and di(C<sub>1</sub>-C<sub>4</sub>)alkylamino;

Z<sup>1</sup> is a divalent moiety selected from the group consisting of (C<sub>1</sub>-C<sub>3</sub>)alkylene;


Z<sup>2</sup> is a divalent moiety selected from the group consisting of -O-, -S- and -N(R<sup>3</sup>)- wherein R<sup>3</sup> is a member selected from the group consisting of H, halogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)haloalkyl, (C<sub>1</sub>-C<sub>4</sub>)haloalkoxy, nitro, cyano, (C<sub>1</sub>-C<sub>4</sub>)acyl, amino, (C<sub>1</sub>-C<sub>4</sub>)alkylamino, and di(C<sub>1</sub>-C<sub>4</sub>)alkylamino; and

N<sup>Het</sup> is a substituted or unsubstituted 4-, 5-, 6-, or 7-membered nitrogen heterocycle.

Claims 6 -7 (canceled).

Claim 8 (currently amended): A method in accordance with claim 5 [[7]], wherein X<sup>1</sup>, X<sup>3</sup>, X<sup>4</sup>, Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup> and Y<sup>4</sup> are all CH; Z<sup>2</sup> is -S-, and N<sup>Het</sup> is a substituted 6-membered nitrogen heterocycle.

Claim 9 (original): A method in accordance with claim 5, wherein said compound has the formula:



wherein

the subscripts m and n are independently integers of from 0 to 3;

R<sup>1</sup> and R<sup>2</sup> are substituents independently selected from the group consisting of halogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)alkylthio, (C<sub>1</sub>-C<sub>4</sub>)haloalkyl, (C<sub>1</sub>-C<sub>4</sub>)haloalkoxy, nitro, cyano, (C<sub>1</sub>-C<sub>4</sub>)acyl, amino, (C<sub>1</sub>-C<sub>4</sub>)alkylamino, and di(C<sub>1</sub>-C<sub>4</sub>)alkylamino; and

$R^3$  is a substituent selected from the group consisting of (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)haloalkyl and (C<sub>1</sub>-C<sub>4</sub>)acyl.

Claim 10 (original): A method in accordance with claim 9, wherein m is 0 and n is 1.


Claim 11 (original): A method in accordance with claim 9, wherein m is 0, n is 1 and  $R^2$  is selected from the group consisting of halogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)alkylthio and (C<sub>1</sub>-C<sub>4</sub>)haloalkyl.

Claim 12 (original): A method in accordance with claim 9, wherein m is 0, n is 1 and  $R^2$  is selected from the group consisting of halogen and (C<sub>1</sub>-C<sub>4</sub>)alkylthio.

Claim 13 (original): A method in accordance with claim 5, wherein said compound is selected from the group consisting of methiothepin, octoclotheptin and pharmaceutically acceptable salts thereof.

Claims 14 -28 (canceled).

Claim 29 (currently amended): A method for treating CMV infection in a human, comprising administering to the human an effective amount of a US 28 receptor modulator capable of blocking or inhibiting the binding of a chemokine to the US28 receptor ~~[[,]]~~ wherein ~~said modulator is a small organic compound having a molecular weight of less than 800 daltons~~ and said administering slows the progression of CMV dissemination in the human and wherein said compound has the formula:



wherein

the subscripts m and n are independently integers of from 0 to 3;

R<sup>1</sup> and R<sup>2</sup> are substituents independently selected from the group consisting of halogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)alkylthio, (C<sub>1</sub>-C<sub>4</sub>)haloalkyl, (C<sub>1</sub>-C<sub>4</sub>)haloalkoxy, nitro, cyano, (C<sub>1</sub>-C<sub>4</sub>)acyl, amino, (C<sub>1</sub>-C<sub>4</sub>)alkylamino, and di(C<sub>1</sub>-C<sub>4</sub>)alkylamino; and

R<sup>3</sup> is a substituent selected from the group consisting of (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)haloalkyl and (C<sub>1</sub>-C<sub>4</sub>)acyl.

Claim 30 (canceled).

Claim 31 (previously presented): A method in accordance with claim 29, wherein m is 0 and n is 1.

Claim 32 (currently amended): A method in accordance with claim 29 [[30]], wherein m is 0, n is 1 and R<sup>2</sup> is selected from the group consisting of halogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)alkylthio and (C<sub>1</sub>-C<sub>4</sub>)haloalkyl.

Claim 33 (previously presented): A method in accordance with claim 32, wherein m is 0, n is 1 and R<sup>2</sup> is selected from the group consisting of halogen and (C<sub>1</sub>-C<sub>4</sub>)alkylthio.

Claim 34 (previously presented): A method in accordance with claim 29, wherein said compound is selected from the group consisting of methiothepin, octoclotheptin and pharmaceutically acceptable salts thereof.

Claim 35 (previously presented): A method in accordance with claim 29, wherein the molecular weight is between 300 and 600 daltons.

Claim 36 (previously presented): A method in accordance with claim 5, wherein the molecular weight is between 300 and 600 daltons.